Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by ...

Blue light cystoscopy had a statistically significant reduction in risk of recurrence versus white light cystoscopy in ...

Cancer research saved my daughter’s life, and despite setbacks, we must support these efforts to ensure more lives are saved ...

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found ...

March is Myeloma Awareness Month, a time to recognize the subtle but serious symptoms of multiple myeloma, including persistent fatigue, unexplained bone pain and anemia. Since diagnosis is often ...

Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate.

Panelists discuss how the term "late-line" in relapsed/refractory multiple myeloma typically refers to patients who have progressed through multiple previous treatment regimens, indicating a more ...

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell ...

Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in ...

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...

After my last fall, where I broke both my upper front teeth and had abrasions on my face, I had to go to the ER to be checked ...